Mariner, Jeffrey C.;
Jones, Bryony A.;
Rich, Karl M.;
Thevasagayam, Samuel;
Anderson, John;
Jeggo, Martyn;
Cai, Yi;
Peters, Andrew R.;
Roeder, Peter L.
The Opportunity To Eradicate Peste des Petits Ruminants
Sie können Bookmarks mittels Listen verwalten, loggen Sie sich dafür bitte in Ihr SLUB Benutzerkonto ein.
Medientyp:
E-Artikel
Titel:
The Opportunity To Eradicate Peste des Petits Ruminants
Beteiligte:
Mariner, Jeffrey C.;
Jones, Bryony A.;
Rich, Karl M.;
Thevasagayam, Samuel;
Anderson, John;
Jeggo, Martyn;
Cai, Yi;
Peters, Andrew R.;
Roeder, Peter L.
Erschienen:
The American Association of Immunologists, 2016
Erschienen in:
The Journal of Immunology, 196 (2016) 9, Seite 3499-3506
Sprache:
Englisch
DOI:
10.4049/jimmunol.1502625
ISSN:
1550-6606;
0022-1767
Entstehung:
Anmerkungen:
Beschreibung:
AbstractPeste des petits ruminants (PPR) is a highly infectious disease of sheep and goats that is caused by PPR virus, a member of the genus Morbillivirus that includes the viruses that cause rinderpest (RP) in cattle. RP was the first animal disease to be globally eradicated in 2011 and is only the second disease, after smallpox, to have ever been eradicated. PPR is one of the principal constraints to small ruminant production in Africa, Asia, and the Middle East. The epidemiology of PPR and RP as well as the technologies available for their diagnosis and control are similar. The conditions that favored the eradication of RP are also largely present for PPR. In this work, we outline the evolving strategy for eradication in light of current opportunities and challenges, as well as the lessons from other eradication programs in animal and human health. The global PPR situation and technology for its control are summarized. A strategy based on the lessons from previous eradication efforts that integrate epidemiology, social science, and economics as tools to target and motivate vaccination is summarized. Major aspects of the cost and benefit-cost analysis of the indicated program are presented. The overall undiscounted cost of eradication was estimated as $3.1 billion, and the benefit-cost ratio for the most likely scenario was estimated at 33.8. We close with a discussion of the possible next steps.